Immuno-Oncology Platform

The discovery of new immunotherapeutic agents requires a suite of in vitro and in vivo assays to investigate the effects on tumor cells and immune cells. Reaction Biology’s immuno-oncology platform enables researchers to test new drug candidates for their potency to modulate the immune system and ultimately reduce tumor growth in cell-based and animal-based models.